NCT05807113 is a NA clinical trial of Atopi intensive care BNO 3731 in Atopic Diathesis, sponsored by Bionorica SE.

Who is sponsoring NCT05807113?

NCT05807113 is sponsored by Bionorica SE.

What drugs are being tested in NCT05807113?

Interventions in NCT05807113: Atopi intensive care BNO 3731, Benchmark product.

What condition does NCT05807113 study?

NCT05807113 studies Atopic Diathesis, Eczema-prone Skin.

Is NCT05807113 still recruiting?

NCT05807113 is currently completed. Last updated 11 April 2023.

Last reviewed 2023-04-11 · How we verify

NCT05807113

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 5 Days of Use on Subjects With Atopic Dermatitis

Completed NA Last updated 11 April 2023

What this trial tests

NA trial testing Atopi intensive care BNO 3731 in Atopic Diathesis in 44 participants. Completed in 22 February 2022.

Timeline

15 February 2022

Primary endpoint
22 February 2022

22 February 2022

Quick facts

Lead sponsor	Bionorica SE
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	44
Start date	15 February 2022
Primary completion	22 February 2022
Estimated completion	22 February 2022
Sites	1 location across Germany

Drugs / interventions tested

Atopi intensive care BNO 3731
Benchmark product

Conditions studied

Atopic Diathesis — all drugs for Atopic Diathesis →
Eczema-prone Skin — all drugs for Eczema-prone Skin →

Sponsor

Bionorica SE — full company profile →

Who can join

Adults 6 Months to 65, any sex, with Atopic Diathesis or Eczema-prone Skin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to compare the efficacy and tolerability and of a cosmetic product to one that is already available on the market (benchmark product). Efficacy is assessed by instrumental measurements of skin condition, clinical examinations, and questionnaires.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical Measurement of Transepidermal Water Loss.
Kundu D, Jayaraman A, Sen CK. · · 2026 · cited 4× · PMID 40476522 · DOI 10.1089/wound.2024.0148

Verify or expand the search:

Other Bionorica SE trials

Trials by the same sponsor.

NCT06211049 — Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea · Phase 3 · completed
NCT05790083 — Skin Efficacy and Tolerability of a Cosmetic Product Combination Over 3 Months in Subjects With Atopic Eczema · NA · unknown
NCT05786976 — Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 4 Weeks of Use on Subjects With Atopic Dermatitis · NA · completed
NCT03756974 — BX-1 in Spasticity Due to Multiple Sclerosis · Phase 3 · completed
NCT02746042 — Sinupret Extract Coated Tablets in Chronic Rhinosinusitis · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05807113 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bionorica SE
Last refreshed: 11 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05807113.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing